Madrigal Pharma’s Q3 profit missed expectations, while revenues were in line with expectations. – Madrigal Pharma (NASDAQ: ) missed Q3 analyst estimates. Revenue remains at the same level as forecasted. According to reports on Monday

Madrigal Pharma’s earnings per share (EPS) was $-5.34 on revenue of $0.00. Analyst consensus compiled by Expectations for the upcoming release: Previously, the figure was $-4.90 per share based on $0 earnings.

Shares of Madrigal Pharma fell 0.54% to $146.09.

Apart from Madrigal Pharma, there are other companies too. Markets report this month’s earnings in the healthcare sector of the NASDAQ Stock Exchange

Eli Lilly previously estimated Q3 earnings at $0.1 per share on revenue of $9.5B, and $-0.2 on revenue of $8.97B.

Meanwhile, UnitedHealth’s most recently reported performance beat analyst forecasts. Q3 earnings were $6.56 per share on revenue of $92.4B, beating analyst estimates for 2020. expects earnings per share to be around $6.33 based on revenue of $91.42B.

Follow the latest developments in company profits with the Earnings Calendar

Leave a Reply

Your email address will not be published. Required fields are marked *